{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:12:41Z","timestamp":1783570361558,"version":"3.55.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/IG\/9-2023-0000559"],"award-info":[{"award-number":["EMDR\/IG\/9-2023-0000559"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06982-6","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:36:37Z","timestamp":1775712997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redesigning CAR therapy to tackle immune effector cell-associated hematotoxicity"],"prefix":"10.1007","volume":"105","author":[{"given":"Muhamad Shafi","family":"Kooniyil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav Thomas","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthuganesh","family":"Muthuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"6982_CR1","doi-asserted-by":"crossref","unstructured":"Maude S (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. Mass Medical SocSL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, P Bader, MR VernerisNew England Journal of Medicine, 2018\u2022Mass Medical Soc 378, 439\u2013448","DOI":"10.1056\/NEJMoa1709866"},{"key":"6982_CR2","doi-asserted-by":"crossref","unstructured":"Neelapu SS et al (2017) Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nature Reviews Clinical Oncology 2017 15:1 15, 47\u201362","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"6982_CR3","doi-asserted-by":"crossref","unstructured":"Haydu JE, Abramson JS (2021) CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions. J Cancer Metastasis Treat 2021;7:36. 7, N\/A-N\/A","DOI":"10.20517\/2394-4722.2021.39"},{"key":"6982_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","author":"K Rejeski","year":"2023","unstructured":"Rejeski K et al (2023) Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. https:\/\/doi.org\/10.1182\/blood.2023020578","journal-title":"Blood"},{"key":"6982_CR5","doi-asserted-by":"crossref","unstructured":"Hay K Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. ashpublications.orgKA Hay, LA Hanafi, D Li, J Gust, WC Liles, MM Wurfel, JA L\u00f3pez, J Chen, D ChungBlood, The Journal of the American Society of Hematology, 2017\u2022ashpublications.org at https:\/\/ashpublications.org\/blood\/article-abstract\/130\/21\/2295\/36661&gt","DOI":"10.1182\/blood-2017-06-793141"},{"key":"6982_CR6","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","volume":"8","author":"K Rejeski","year":"2024","unstructured":"Rejeski K et al (2024) Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv 8:1857\u20131868","journal-title":"Blood Adv"},{"key":"6982_CR7","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1200\/JCO.2024.42.16_suppl.7041","volume":"42","author":"M Zenner","year":"2024","unstructured":"Zenner M et al (2024) Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes. J Clin Oncol 42:7041\u20137041","journal-title":"J Clin Oncol"},{"key":"6982_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2444673","author":"JM Wang","year":"2024","unstructured":"Wang JM et al (2024) Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666X.2024.2444673","journal-title":"Expert Rev Clin Immunol"},{"key":"6982_CR9","doi-asserted-by":"crossref","unstructured":"Zhang X et al Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7. ElsevierX Zhang, Q Wang, Y Liu, J Yang, J Li, H Liu, J Li, P LuBlood, 2023\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497123134793","DOI":"10.1182\/blood-2023-185361"},{"key":"6982_CR10","unstructured":"Cappell K et al Long-term outcomes following CAR T cell therapy: what we know so far. nature.comKM Cappell, JN KochenderferNature reviews Clinical oncology, 2023\u2022nature.com at https:\/\/www.nature.com\/articles\/s41571-023-00754-1&gt"},{"key":"6982_CR11","doi-asserted-by":"crossref","unstructured":"Kochenderfer J Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. ashpublications.orgJN Kochenderfer, WH Wilson, JE Janik, ME Dudley, M Stetler-Stevenson, SA FeldmanBlood, The Journal of the American Society of Hematology, 2010\u2022ashpublications.org at https:\/\/ashpublications.org\/blood\/article-abstract\/116\/20\/4099\/28095&gt","DOI":"10.1182\/blood-2010-04-281931"},{"key":"6982_CR12","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/S2352-3026(24)00377-6","volume":"12","author":"H Jain","year":"2025","unstructured":"Jain H et al (2025) Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1\/2 study. Lancet Haematol 12:e282\u2013e293","journal-title":"Lancet Haematol"},{"key":"6982_CR13","unstructured":"Rejeski K et al Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. thelancet.comK Rejeski, MD Jain, NN Shah, MA Perales, M SubkleweThe Lancet Haematology, 2024\u2022thelancet.com at https:\/\/www.thelancet.com\/journals\/lanhae\/article\/PIIS2352-3026(24)00077-2\/fulltext&gt"},{"key":"6982_CR14","unstructured":"Si X Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective. ElsevierX Si, T Gu, L Liu, Y Huang, Y Han, P Qian, H HuangCancer Letters, 2022\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0304383522004074?casa_token=7tFO-zPrTwoAAAAA:XbAr0ybxtIdMJvWbqWIfiElgMTDks9Jsp2DFfCyulzw_vGnIJeug6rrAo41qAd7xD8AYWsBN4g&gt"},{"key":"6982_CR15","doi-asserted-by":"crossref","unstructured":"Drillet G et al Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. ashpublications.orgG Drillet, F Lhomme, S De Guibert, G Manson, R HouotBlood Advances, 2023\u2022ashpublications.org at https:\/\/ashpublications.org\/bloodadvances\/article-abstract\/7\/4\/537\/486125","DOI":"10.1182\/bloodadvances.2022008066"},{"key":"6982_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/14787210.2022.2128762","volume":"20","author":"G Telli Dizman","year":"2022","unstructured":"Telli Dizman G et al (2022) Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. Expert Rev Anti Infect Ther 20:1455\u20131476","journal-title":"Expert Rev Anti Infect Ther"},{"key":"6982_CR17","doi-asserted-by":"crossref","unstructured":"Miller K Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. nature.comKC Miller, PC Johnson, JS Abramson, JD Soumerai, AJ Yee, AR Branagan, EK O\u2019DonnellBlood Cancer Journal, 2022\u2022nature.com at https:\/\/www.nature.com\/articles\/s41408-022-00741-2&gt","DOI":"10.1038\/s41408-022-00741-2"},{"key":"6982_CR18","doi-asserted-by":"crossref","unstructured":"Rejeski K et al An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on. journals.lww.com at https:\/\/journals.lww.com\/hemasphere\/fulltext\/2023\/05000\/an_international_survey_on_grading,_diagnosis,_and.6.aspx","DOI":"10.1097\/HS9.0000000000000889"},{"key":"6982_CR19","doi-asserted-by":"crossref","unstructured":"Cella D The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. ElsevierD Cella, J Kallich, A McDermott, X XuAnnals of Oncology, 2004\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0923753419618569","DOI":"10.1093\/annonc\/mdh235"},{"key":"6982_CR20","unstructured":"Fried S et al Early and late hematologic toxicity following CD19 CAR-T cells. nature.comS Fried, A Avigdor, B Bielorai, A Meir, MJ Besser, J Schachter, A Shimoni, A Nagler, A TorenBone marrow transplantation, 2019\u2022nature.com at https:\/\/idp.nature.com\/authorize\/casa?redirect_uri=https:\/\/www.nature.com\/articles\/s41409-019-0487-3&casa_token=4i3GNyM_TKkAAAAA:zGb2aS1FeYGxfMQJ_Ijw8vwFVRx6PAUpJsa6JwfG6seNuuEcE7zZ5139RQk6avsB26eedHrm4UQF0uAx&gt"},{"key":"6982_CR21","doi-asserted-by":"crossref","unstructured":"Jain T et al Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. ashpublications.orgT Jain, A Knezevic, M Pennisi, Y Chen, JD Ruiz, TJ Purdon, SM Devlin, M Smith, GL ShahBlood advances, 2020\u2022ashpublications.org at https:\/\/ashpublications.org\/bloodadvances\/article-abstract\/4\/15\/3776\/461775","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"6982_CR22","doi-asserted-by":"crossref","unstructured":"Johnsrud A et al Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. ashpublications.orgA Johnsrud, J Craig, J Baird, J Spiegel, L Muffly, J Zehnder, J Tamaresis, R NegrinBlood advances, 2021\u2022ashpublications.org at https:\/\/ashpublications.org\/bloodadvances\/article-abstract\/5\/21\/4465\/476900","DOI":"10.1182\/bloodadvances.2021004716"},{"key":"6982_CR23","doi-asserted-by":"crossref","unstructured":"Mezquita L et al Cytopenias in CAR-T cell therapy and use of transfusion resources in adult patients with lymphoproliferative disorders. ElsevierL Mezquita, ME Mingot, P Alcalde, P S\u00e1nchez-Llorca, J Camu\u00f1a-Correa, JL RegueraBlood, 2021\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497121051740","DOI":"10.1182\/blood-2021-149738"},{"key":"6982_CR24","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3233\/THC-220537","volume":"31","author":"Y Xia","year":"2023","unstructured":"Xia Y et al (2023) The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: a systematic review and meta-analysis. Technol Health Care 31:2363\u20132380","journal-title":"Technol Health Care"},{"key":"6982_CR25","doi-asserted-by":"crossref","unstructured":"Rejeski K CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. ashpublications.orgK Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, D Mougiakakos, L Fr\u00f6lichBlood, The Journal of the American Society of Hematology, 2021\u2022ashpublications.org at https:\/\/ashpublications.org\/blood\/article-abstract\/138\/24\/2499\/476241&gt","DOI":"10.1182\/blood.2020010543"},{"key":"6982_CR26","doi-asserted-by":"crossref","unstructured":"Zhang B (2024) Bone marrow involvement in solid tumors-a retrospective observational study. frontiersin.orgB Zhang, L Jin, D Wu, J Xu, S Guo, J Li, T ZhangFrontiers in Oncology, 2025\u2022frontiersin.org 14","DOI":"10.3389\/fonc.2024.1434709"},{"key":"6982_CR27","doi-asserted-by":"crossref","unstructured":"Yang R et al (2024) Mechanism and clinical progression of solid tumors bone marrow metastasis. frontiersin orgR Yang L Jia J CuiFrontiers Pharmacol 2024\u2022frontiersin org 15","DOI":"10.3389\/fphar.2024.1390361"},{"key":"6982_CR28","unstructured":"Miller A et al Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Elsevier < https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1465324924006893"},{"key":"6982_CR29","doi-asserted-by":"crossref","unstructured":"Myers R Clinical factors associated with prolonged cytopenias after CD19 chimeric antigen receptor T-cell therapy for pediatric B-cell acute lymphoblastic leukemia. ElsevierRM Myers, Y Li, A Lamble, EM Hsieh, S John, G Dolan, H Liu, L Chen, J SheppardBlood, 2024\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497124075852","DOI":"10.1182\/blood-2024-202027"},{"key":"6982_CR30","doi-asserted-by":"crossref","unstructured":"Zhou J et al (2022) Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. frontiersin.org 13","DOI":"10.3389\/fimmu.2022.997589"},{"key":"6982_CR31","doi-asserted-by":"crossref","unstructured":"Zhang Y (2026) Barriers and Strategies to Enhance CAR-T Cell Infiltration in Solid Tumours: A Systematic Review. Wiley Online LibraryY Zhang, H Sun, L Zhao, N Zhao, Z Chen, L He, Z Guo, J YuImmunology, 2026\u2022Wiley Online Library 0, 1\u201317","DOI":"10.1111\/imm.70094"},{"key":"6982_CR32","unstructured":"Kwon N et al Overcoming solid-tumor barriers: armored CAR-T cell therapy. cell.comN Kwon, YY ChenTrends in Cancer, 2025\u2022cell.com at https:\/\/www.cell.com\/trends\/cancer\/abstract\/S2405-8033(25)00207-9&gt"},{"key":"6982_CR33","first-page":"1850","volume":"8","author":"HR Mirzaei","year":"2017","unstructured":"Mirzaei HR et al (2017) Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives. Elsevier 8:1850","journal-title":"Elsevier"},{"key":"6982_CR34","doi-asserted-by":"publisher","unstructured":"Li Y, Mei H (2022) Whole-process management of complications during CAR-T therapy. Hematology and Oncology Discovery. https:\/\/doi.org\/10.15212\/hod-2022-0005","DOI":"10.15212\/hod-2022-0005"},{"key":"6982_CR35","doi-asserted-by":"crossref","unstructured":"Ahmed N et al Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy. ncbi.nlm.nih.govN Ahmed, O Oluwole, Z Mahmoudjafari, N Suleman, JP McGuirkClinical Hematology International, 2024\u2022ncbi.nlm.nih.gov at https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11086990\/","DOI":"10.46989\/001c.115932"},{"key":"6982_CR36","doi-asserted-by":"crossref","unstructured":"Reinhardt B et al (2073) -4409\/12\/4\/531> Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. mdpi.comB Reinhardt, P Lee, JP SasineCells, 2023\u2022mdpi.com at https:\/\/www.mdpi.com\/","DOI":"10.3390\/cells12040531"},{"key":"6982_CR37","doi-asserted-by":"crossref","unstructured":"Rejeski K Applying the Novel EHA\/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections. ElsevierK Rejeski, DK Hansen, Y Wang, G Iacoboni, E Bachy, R Bansal, O Penack, F MuellerBlood, 2023\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497123049637","DOI":"10.1182\/blood-2023-180607"},{"key":"6982_CR38","doi-asserted-by":"crossref","unstructured":"Rejeski K et al The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. ncbi.nlm.nih.govK Rejeski, A Perez, G Iacoboni, O Penack, V B\u00fccklein, L Jentzsch, D MougiakakosJournal for immunotherapy of cancer, 2022.ncbi.nlm. nih.gov at https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9114843\/","DOI":"10.1136\/jitc-2021-004475"},{"key":"6982_CR39","doi-asserted-by":"crossref","unstructured":"Rejeski K et al (2023) The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol 16","DOI":"10.1186\/s13045-023-01465-x"},{"key":"6982_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41409-024-02278-3","volume":"59","author":"EC Liang","year":"2024","unstructured":"Liang EC et al (2024) Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity. Bone Marrow Transplant 59:910\u2013917","journal-title":"Bone Marrow Transplant"},{"key":"6982_CR41","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2025028833","author":"K Rejeski","year":"2025","unstructured":"Rejeski K et al (2025) T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. https:\/\/doi.org\/10.1182\/BLOOD.2025028833","journal-title":"Blood"},{"key":"6982_CR42","doi-asserted-by":"crossref","unstructured":"Juluri K (2055) \/477390> Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. ashpublications.orgKR Juluri, QV Wu, J Voutsinas, J Hou, AV Hirayama, E Mullane, N Miles, DG MaloneyBlood Advances, 2022\u2022ashpublications.org at https:\/\/ashpublications.org\/bloodadvances\/article-abstract\/6\/7\/","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"6982_CR43","doi-asserted-by":"crossref","unstructured":"Iacoboni G (2017) Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell. ascopubs.orgG Iacoboni, V Navarro, A\u00c1 Mart\u00edn-L\u00f3pez, K Rejeski, M Kwon, KA Jalowiec, P AmatJournal of Clinical Oncology, 2024\u2022ascopubs.org 42, 205\u2013217","DOI":"10.1200\/JCO.23.01097"},{"key":"6982_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT (2019) Emapalumab: first global approval. Drugs 79:99\u2013103","journal-title":"Drugs"},{"key":"6982_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s40778-018-0139-3","volume":"4","author":"DE Morales-Mantilla","year":"2018","unstructured":"Morales-Mantilla DE, King KY (2018) The role of interferon-Gamma in hematopoietic stem cell development, homeostasis, and disease. Curr Stem Cell Rep 4:264\u2013271","journal-title":"Curr Stem Cell Rep"},{"key":"6982_CR46","doi-asserted-by":"crossref","unstructured":"Wang L et al (2021) New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Front Oncol 11","DOI":"10.3389\/fonc.2021.702644"},{"key":"6982_CR47","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjh.18747","volume":"202","author":"W Kitamura","year":"2023","unstructured":"Kitamura W et al (2023) Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. Br J Haematol 202:294\u2013307","journal-title":"Br J Haematol"},{"key":"6982_CR48","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1182\/blood-2014-04-568451","volume":"124","author":"AM De Bruin","year":"2014","unstructured":"De Bruin AM et al (2014) Impact of interferon-\u03b3 on hematopoiesis. Blood 124:2479\u20132486","journal-title":"Blood"},{"key":"6982_CR49","doi-asserted-by":"crossref","unstructured":"Mitroulis I et al (2020) Regulation of the Bone Marrow Niche by Inflammation. Front Immunol 11","DOI":"10.3389\/fimmu.2020.01540"},{"key":"6982_CR50","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.it.2019.09.006","volume":"40","author":"S Saw","year":"2019","unstructured":"Saw S et al (2019) Metalloproteases: on the watch in the hematopoietic niche. Trends Immunol 40:1053\u20131070","journal-title":"Trends Immunol"},{"key":"6982_CR51","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3892\/mmr.2014.2374","volume":"10","author":"Y Wu","year":"2014","unstructured":"Wu Y et al (2014) Platelet-derived growth factor promotes osteoblast proliferation by activating G-protein-coupled receptor kinase interactor-1. Mol Med Rep 10:1349\u20131354","journal-title":"Mol Med Rep"},{"key":"6982_CR52","unstructured":"Flugel C et al Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. nature.comCL Flugel, RG Majzner, G Krenciute, G Dotti, SR Riddell, DL Wagner, M Abou-el-EneinNature Reviews Clinical Oncology, 2023\u2022nature.com at https:\/\/idp.nature.com\/authorize\/casa?redirect_uri=https:\/\/www.nature.com\/articles\/s41571-022-00704-3&casa_token=G7Bd62ma1kgAAAAA:vtI6glq08FoCVjkmL6zPv8857SjFyt8ns8d68ip4aR6lO7GFJBWQgC6G1tUVgSeluqz7lvhwtCyMk20j&gt"},{"key":"6982_CR53","unstructured":"Luo J et al Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. ncbi.nlm.nih.govJ Luo, X ZhangFrontiers in Oncology, 2024\u2022ncbi.nlm.nih.gov at https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11196618\/"},{"key":"6982_CR54","doi-asserted-by":"crossref","unstructured":"Jain T et al How I treat cytopenias after CAR T-cell therapy. ashpublications.orgT Jain, TS Olson, FL LockeBlood, The Journal of the American Society of Hematology, 2023\u2022ashpublications.org at https:\/\/ashpublications.org\/blood\/article-abstract\/141\/20\/2460\/494597","DOI":"10.1182\/blood.2022017415"},{"key":"6982_CR55","doi-asserted-by":"crossref","unstructured":"Majzner R et al Tumor antigen escape from CAR T-cell therapy. AACRRG Majzner, CL MackallCancer discovery, 2018\u2022AACR at https:\/\/aacrjournals.org\/cancerdiscovery\/article-abstract\/8\/10\/1219\/6227","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"6982_CR56","unstructured":"Sayadmanesh A Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer. ElsevierA Sayadmanesh, V Yekehfallah, A Valizadeh, A Abedelahi, H Shafaei, D ShanehbandiInternational Immunopharmacology, 2023\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1567576923014194?casa_token=zG3zJ1DgB_4AAAAA:_GwIDSJe_52eocWY8VIr2joffol9fDqEowC6ZUad2-KAHx35QDDdjFmdSxch8VfvVt9DiJe1_g&gt"},{"key":"6982_CR57","doi-asserted-by":"crossref","unstructured":"Tao R et al (2024) Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology. Front Immunol 15","DOI":"10.3389\/fimmu.2024.1354825"},{"key":"6982_CR58","doi-asserted-by":"crossref","unstructured":"Li C et al Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy. academic.oup.comC Li, H Mei, Y HuBriefings in functional genomics, 2020\u2022academic.oup.com at https:\/\/academic.oup.com\/bfg\/article-abstract\/19\/3\/175\/5707552","DOI":"10.1093\/bfgp\/elz042"},{"key":"6982_CR59","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1182\/blood.2024024104","volume":"144","author":"MJ Frigault","year":"2024","unstructured":"Frigault MJ et al (2024) Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37\u2009+\u2009lymphoid malignancies. Blood 144:1153\u20131167","journal-title":"Blood"},{"key":"6982_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12616","author":"G Kaplanski","year":"2017","unstructured":"Kaplanski G (2017) Interleukin-18: Biological properties and role in disease pathogenesis. Immunological Reviews. https:\/\/doi.org\/10.1111\/imr.12616","journal-title":"Immunological Reviews"},{"key":"6982_CR61","doi-asserted-by":"crossref","unstructured":"Kessel C et al (2025) Weal and woe of interleukin-18 in the T cell therapy of cancer. J Immunother Cancer 13","DOI":"10.1136\/jitc-2024-010545"},{"key":"6982_CR62","doi-asserted-by":"crossref","unstructured":"Howard JE et al (2021) IFNs induce prolonged hematopoietic suppression via IL-18-induced cell death during shock-like Ehrlichial infection. Journal of Immunology 206:107.15-107.15","DOI":"10.4049\/jimmunol.206.Supp.107.15"},{"key":"6982_CR63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/MOH.0000000000000149","volume":"22","author":"JL Zhao","year":"2015","unstructured":"Zhao JL, Baltimore D (2015) Regulation of stress-induced hematopoiesis. Curr Opin Hematol 22:286\u2013292","journal-title":"Curr Opin Hematol"},{"key":"6982_CR64","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood-2003-01-0114","volume":"102","author":"C Dufour","year":"2003","unstructured":"Dufour C et al (2003) TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102:2053\u20132059","journal-title":"Blood"},{"key":"6982_CR65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1557\/PROC-751-Z4.6","volume":"975","author":"NP Weng","year":"2002","unstructured":"Weng NP et al (2002) IL-15 is a growth factor and an activator of CD8 memory T cells. Wiley Online Libr 975:46\u201356","journal-title":"Wiley Online Libr"},{"key":"6982_CR66","doi-asserted-by":"crossref","unstructured":"Gust J et al (2020) Cytokines in CAR T cell\u2013associated neurotoxicity. frontiersin.orgJ Gust, R Ponce, WC Liles, GA Garden, CJ TurtleFrontiers in immunology, 2020\u2022frontiersin.org 11, 1","DOI":"10.3389\/fimmu.2020.577027"},{"key":"6982_CR67","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Moreno I (2024) Tethered IL15-IL15R\u03b1 augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. pmc.ncbi.nlm.nih.govI S\u00e1nchez-Moreno, A Lasarte-Cia, C Mart\u00edn-Otal, N Casares, F Navarro, M Gorraiz, P Sarri\u00f3nJournal for Immunotherapy of Cancer, 2024\u2022pmc.ncbi.nlm.nih.gov 12, 8572","DOI":"10.1136\/jitc-2023-008572"},{"key":"6982_CR68","doi-asserted-by":"publisher","first-page":"107671","DOI":"10.4254\/wjh.v17.i9.107671","volume":"17","author":"CS Wu","year":"2025","unstructured":"Wu CS et al (2025) Targeting glypican-3 as a new frontier in liver cancer therapy. World J Hepatol 17:107671","journal-title":"World J Hepatol"},{"key":"6982_CR69","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO-24-02081","volume":"43","author":"S Ouladan","year":"2025","unstructured":"Ouladan S, Orouji E (2025) Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy. J Clin Oncol 43:994\u20131005","journal-title":"J Clin Oncol"},{"key":"6982_CR70","unstructured":"Li Y IL-15 in CAR engineering: Striking an efficacy\u2013safety balance. cell.comYR Li, Y Zhu, L YangTrends in Molecular Medicine, 2025\u2022cell.com at https:\/\/www.cell.com\/trends\/molecular-medicine\/fulltext\/S1471-4914(25)00137-6&gt"},{"key":"6982_CR71","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4103623\/v1","author":"A Heczey","year":"2024","unstructured":"Heczey A et al (2024) Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4103623\/v1","journal-title":"Res Sq"},{"key":"6982_CR72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194631","author":"S Bailey","year":"2026","unstructured":"Bailey S et al (2026) Fanning the flames: IFN-\u03b3 fuels CAR-T inflammation and cytopenia. jci.orgSR Bailey, MV MausThe. J Clin Invest 2026\u2022jciorg. https:\/\/doi.org\/10.1172\/JCI194631","journal-title":"J Clin Invest 2026\u2022jciorg"},{"key":"6982_CR73","doi-asserted-by":"crossref","unstructured":"Zhang S An IL-10-incorporated predictive model for late immune effector cell-associated hematotoxicity following CAR-T therapy in B-cell malignancies. ElsevierS Zhang, L Huang, H Luo, S Ye, X ZhouBlood, 2025\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497125069149","DOI":"10.1182\/blood-2025-4167"},{"key":"6982_CR74","unstructured":"Teachey D Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. AACRDT Teachey, SF Lacey, PA Shaw, JJ Melenhorst, SL Maude, N Frey, E PequignotCancer discovery, 2016\u2022AACR at https:\/\/aacrjournals.org\/cancerdiscovery\/article-abstract\/6\/6\/664\/5936"},{"key":"6982_CR75","unstructured":"Norelli M et al Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. nature.comM Norelli, B Camisa, G Barbiera, L Falcone, A Purevdorj, M Genua, F Sanvito, M PonzoniNature medicine, 2018\u2022nature.com at https:\/\/idp.nature.com\/authorize\/casa?redirect_uri=https:\/\/www.nature.com\/articles\/s41591-018-0036-4&casa_token=kgn-MM-XevAAAAAA:kDHXaq71CCRs7L5rkfKDD4dMpM67k_Qu656GKK1bRjDas-arLm_ODl78MYipLQ8_GXnd1OGk1KEmmn81&gt"},{"key":"6982_CR76","doi-asserted-by":"crossref","unstructured":"Brudno J et al Toxicities of chimeric antigen receptor T cells: recognition and management. ashpublications.orgJN Brudno, JN KochenderferBlood, The Journal of the American Society of Hematology, 2016\u2022ashpublications.org at https:\/\/ashpublications.org\/blood\/article-abstract\/127\/26\/3321\/35340","DOI":"10.1182\/blood-2016-04-703751"},{"key":"6982_CR77","doi-asserted-by":"crossref","unstructured":"Grupp SA (2013) Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. Mass Medical SocSA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, DT Teachey, A ChewNew England Journal of Medicine, 2013\u2022Mass Medical Soc 368, 1509\u20131527","DOI":"10.1056\/NEJMoa1215134"},{"key":"6982_CR78","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Rojas RM et al (2022) Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel. Wiley Online LibraryRM Mart\u00edn-Rojas, I G\u00f3mez\u2010Centuri\u00f3n, R Bailen, M Bastos, F Diaz\u2010Crespo, D CarbonellClinical Case Reports, 2022\u2022Wiley Online Library 10, 5209","DOI":"10.1002\/ccr3.5209"},{"key":"6982_CR79","unstructured":"Khurana A Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. nature.comA Khurana, AC Rosenthal, R Mohty, M Gaddam, R Bansal, MA Hathcock, AN NedvedBlood Cancer Journal, 2024\u2022nature.com at https:\/\/www.nature.com\/articles\/s41408-024-01119-2&gt"},{"key":"6982_CR80","first-page":"569","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith PM et al (2013) The microbial metabolites, short-chain fatty acids, regulate colonic T reg cell homeostasis. Sci (1979) 341:569\u2013573","journal-title":"Sci (1979)"},{"key":"6982_CR81","unstructured":"Takizawa H et al Pathogen-induced TLR4-TRIF innate immune signaling in hematopoietic stem cells promotes proliferation but reduces competitive fitness. cell.com at https:\/\/www.cell.com\/cell-stem-cell\/fulltext\/S1934-5909(17)30239-4&gt"},{"key":"6982_CR82","doi-asserted-by":"crossref","unstructured":"Iwamura C Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis. ashpublications.orgC Iwamura, N Bouladoux, Y Belkaid, A Sher, D JankovicBlood, The Journal of the American Society of Hematology, 2017\u2022ashpublications.org at https:\/\/ashpublications.org\/blood\/article-abstract\/129\/2\/171\/36075","DOI":"10.1182\/blood-2016-06-723742"},{"key":"6982_CR83","first-page":"713","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith M et al (2022) Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Netw Boston 28:713\u2013723","journal-title":"Nat Netw Boston"},{"key":"6982_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24331-1","author":"M Luu","year":"2021","unstructured":"Luu M et al (2021) Microbial short-chain fatty acids modulate CD8\u2009+\u2009T cell responses and improve adoptive immunotherapy for cancer. Nature Communications. https:\/\/doi.org\/10.1038\/s41467-021-24331-1","journal-title":"Nature Communications"},{"key":"6982_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32960-3","author":"Y Hu","year":"2022","unstructured":"Hu Y et al (2022) CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nature communications. https:\/\/doi.org\/10.1038\/s41467-022-32960-3","journal-title":"Nature communications"},{"issue":"4","key":"6982_CR86","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000200","volume":"6","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) Gut microbiota plays pivotal roles in benign and malignant hematopoiesis. Blood Science 6(4):e00200","journal-title":"Blood Science"},{"key":"6982_CR87","doi-asserted-by":"crossref","unstructured":"Fischer JW (2021) CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Front Immunol 12","DOI":"10.3389\/fimmu.2021.693016"},{"key":"6982_CR88","doi-asserted-by":"crossref","unstructured":"Gaut D Granulocyte colony-stimulating factor (G-CSF) interactions with chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma. ElsevierD Gaut, K Tang, M Sim, T Duong, J Sasine, PA YoungBlood, 2019\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497118620373","DOI":"10.1182\/blood-2019-122195"},{"key":"6982_CR89","doi-asserted-by":"crossref","unstructured":"Bindal P et al G-CSF administration is associated with worse treatment response and survival after CAR T-cell therapy. ashpublications.orgP Bindal, P Elavalakanar, CA Trottier, LE Dodge, EK Logan, DJ Sermer, M LeukamBlood, 2022\u2022ashpublications.org at https:\/\/ashpublications.org\/blood\/article\/140\/Supplement%201\/5238\/492500","DOI":"10.1182\/blood-2022-167976"},{"key":"6982_CR90","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/hon.3188","volume":"41","author":"M Cao","year":"2023","unstructured":"Cao M et al (2023) Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T-cell therapy. Hematol Oncol 41:933\u2013941","journal-title":"Hematol Oncol"},{"key":"6982_CR91","doi-asserted-by":"crossref","unstructured":"Kampouri E et al (2023) Infections after chimeric antigen receptor (CAR)-T\u2010cell therapy for hematologic malignancies. Wiley Online LibraryE Kampouri, JS Little, K Rejeski, O Manuel, SP Hammond, JA HillTransplant Infectious Disease, 2023\u2022Wiley Online Library 25","DOI":"10.1111\/tid.14157"},{"key":"6982_CR92","unstructured":"Ozment C Iron overload following red et al blood cell transfusion and its impact on disease severity. ElsevierCP Ozment, JL TuriBiochimica et Biophysica Acta (BBA)-General Subjects, 2009\u2022Elsevier at <https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0304416508002316?casa_token=zsqJEm01GpEAAAAA:ogzKg-GfqBLvfx-ju3nBegrCO7BQ3h8M5HLm7lxEq3sus3IwtpKmRSdrJiNIiVLhJPb68eeKOg&gt"},{"key":"6982_CR93","unstructured":"Wong C et al Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to. Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S014521261830033X?casa_token=lbTMfxDKQykAAAAA:hTb2Ix-2jiQ87VevKm0MJeAqaE2KCpidc6rhtkW3TKtwstWoaYvRUO27qPIhUGAHUy8Dye-d-w&gt"},{"key":"6982_CR94","doi-asserted-by":"crossref","unstructured":"Palumbo GA et al (2021) From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. Front Oncol 11","DOI":"10.3389\/fonc.2021.752192"},{"key":"6982_CR95","first-page":"705","volume":"16","author":"S Si","year":"2020","unstructured":"Si S, Teachey DT (2020) Spotlight on tocilizumab in the treatment of car-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag 16:705\u2013714","journal-title":"Ther Clin Risk Manag"},{"key":"6982_CR96","doi-asserted-by":"crossref","unstructured":"Ferreros P et al (2079) -9721\/10\/3\/41> Interleukin inhibitors in cytokine release syndrome and neurotoxicity secondary to CAR-T therapy. mdpi.comP Ferreros, I TraperoDiseases, 2022\u2022mdpi.com at https:\/\/www.mdpi.com\/","DOI":"10.3390\/diseases10030041"},{"key":"6982_CR97","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14656566.2024.2340738","volume":"25","author":"ZE Walton","year":"2024","unstructured":"Walton ZE et al (2024) Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Expert Opin Pharmacother 25:263\u2013279","journal-title":"Expert Opin Pharmacother"},{"key":"6982_CR98","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/10428194.2021.1881507","volume":"62","author":"A Major","year":"2021","unstructured":"Major A et al (2021) Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma 62:1765\u20131769","journal-title":"Leuk Lymphoma"},{"key":"6982_CR99","doi-asserted-by":"crossref","unstructured":"Mullanfiroze K CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. ashpublications.orgK Mullanfiroze, A Lazareva, J Chu, L Williams, S Burridge, J Silva, R Chiesa, K RaoBlood Advances, 2022\u2022ashpublications.org at https:\/\/ashpublications.org\/bloodadvances\/article-abstract\/6\/16\/4715\/485789","DOI":"10.1182\/bloodadvances.2022007572"},{"key":"6982_CR100","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/ejh.14141","volume":"112","author":"W Wesson","year":"2024","unstructured":"Wesson W et al (2024) Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias. Eur J Haematol 112:538\u2013546","journal-title":"Eur J Haematol"},{"key":"6982_CR101","doi-asserted-by":"crossref","unstructured":"Huarte E Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. AACRE Huarte, RS O\u2019Connor, MT Peel, S Nunez-Cruz, J Leferovich, A Juvekar, Y Yang, L TruongClinical cancer research, 2020\u2022AACR at https:\/\/aacrjournals.org\/clincancerres\/article-abstract\/26\/23\/6299\/82923&gt","DOI":"10.1158\/1078-0432.CCR-20-1739"},{"key":"6982_CR102","doi-asserted-by":"crossref","unstructured":"Guercio M et al (2021) Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies. Front Immunol 12","DOI":"10.3389\/fimmu.2021.755639"},{"key":"6982_CR103","doi-asserted-by":"crossref","unstructured":"Peters D et al (2023) Building safety into CAR-T therapy. Taylor Francis 19","DOI":"10.1080\/21645515.2023.2275457"},{"key":"6982_CR104","doi-asserted-by":"publisher","first-page":"9577","DOI":"10.1021\/acs.jmedchem.0c02054","volume":"64","author":"Y Zheng","year":"2021","unstructured":"Zheng Y et al (2021) Optimization of CAR-T cell-based therapies using small-molecule-based safety switches. J Med Chem 64:9577\u20139591","journal-title":"J Med Chem"},{"key":"6982_CR105","doi-asserted-by":"crossref","unstructured":"Naeem M et al (2023) Explorations of CRISPR\/Cas9 for improving the long-term efficacy of universal CAR-T cells in cancer immunotherapy. Life Sci 316","DOI":"10.1016\/j.lfs.2023.121409"},{"key":"6982_CR106","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-141115","volume":"136","author":"EL Siegler","year":"2020","unstructured":"Siegler EL et al (2020) Efficient gene editing of CART cells with CRISPR-Cas12a for enhanced antitumor efficacy. Blood 136:6\u20137","journal-title":"Blood"},{"key":"6982_CR107","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1515\/hsz-2023-0317","volume":"405","author":"CA Tsiverioti","year":"2024","unstructured":"Tsiverioti CA et al (2024) Beyond CAR T cells: Exploring alternative cell sources for CAR-like cellular therapies. Biol Chem 405:485\u2013515","journal-title":"Biol Chem"},{"key":"6982_CR108","doi-asserted-by":"crossref","unstructured":"Morgan MA et al (2020) Use of Cell and Genome Modification Technologies to Generate Improved Off-the-Shelf CAR T and CAR NK Cells. Front Immunol 11","DOI":"10.3389\/fimmu.2020.01965"},{"key":"6982_CR109","doi-asserted-by":"crossref","unstructured":"Ebrahimiyan H et al (2022) Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol 106","DOI":"10.1016\/j.intimp.2022.108587"},{"key":"6982_CR110","doi-asserted-by":"publisher","first-page":"1464218","DOI":"10.3389\/fcell.2024.1464218","volume":"12","author":"T Huang","year":"2024","unstructured":"Huang T et al (2024) CAR-macrophage: Breaking new ground in cellular immunotherapy. Front Cell Dev Biol 12:1464218","journal-title":"Front Cell Dev Biol"},{"key":"6982_CR111","doi-asserted-by":"crossref","unstructured":"Meyran D et al (2023) TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med 15","DOI":"10.1126\/scitranslmed.abk1900"},{"key":"6982_CR112","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco L et al (2021) Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat Cancer 2:629\u2013642","journal-title":"Nat Cancer"},{"key":"6982_CR113","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2021-149095","volume":"138","author":"MA Wallet","year":"2021","unstructured":"Wallet MA et al (2021) Induced pluripotent stem cell-derived gamma delta CAR-T cells for cancer immunotherapy. Blood 138:2771\u20132771","journal-title":"Blood"},{"key":"6982_CR114","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1182\/blood-2014-08-594796","volume":"125","author":"CA Kuksin","year":"2015","unstructured":"Kuksin CA et al (2015) CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia. Blood 125:2087\u20132094","journal-title":"Blood"},{"key":"6982_CR115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/imr.12920","volume":"298","author":"C Rafia","year":"2020","unstructured":"Rafia C et al (2020) Beyond CAR T cells: engineered V\u03b39V\u03b42 T cells to fight solid tumors. Immunological reviews 298:117\u2013133","journal-title":"Immunological reviews"},{"key":"6982_CR116","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.03.578580","author":"A Cutilli","year":"2024","unstructured":"Cutilli A et al (2024) IFN\u03b3 induces epithelial reprogramming driving CXCL11-mediated T cell migration. bioRxiv. https:\/\/doi.org\/10.1101\/2024.02.03.578580","journal-title":"bioRxiv"},{"key":"6982_CR117","doi-asserted-by":"crossref","unstructured":"Bailey S Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. aacrjournals.orgSR Bailey, S Vatsa, RC Larson, AA Bouffard, I Scarf\u00f2, MC Kann, TR Berger, MB LeickBlood Cancer Discovery, 2022\u2022aacrjournals.org at https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-abstract\/3\/2\/136\/681793","DOI":"10.1158\/2643-3230.BCD-21-0181"},{"key":"6982_CR118","doi-asserted-by":"crossref","unstructured":"Manni S et al (2023) Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun 14","DOI":"10.1038\/s41467-023-38723-y"},{"key":"6982_CR119","doi-asserted-by":"crossref","unstructured":"Li YR et al (2025) Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells. Proc. Natl. Acad. Sci. U. S. A. 122","DOI":"10.1073\/pnas.2517786122"},{"key":"6982_CR120","doi-asserted-by":"publisher","unstructured":"Li YR et al (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. https:\/\/doi.org\/10.1016\/j.medj.2025.100804","DOI":"10.1016\/j.medj.2025.100804"},{"key":"6982_CR121","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"YR Li","year":"2025","unstructured":"Li YR et al (2025) Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol 43:329\u2013344","journal-title":"Nat Biotechnol"},{"key":"6982_CR122","doi-asserted-by":"crossref","unstructured":"Courtney A Facts and Hopes of Chimeric Antigen Receptor\u2013Redirected NK T Cells. aacrjournals.orgAN Courtney, X Zhou, G Tian, Y Wang, LS Metelitsa, G DottiClinical Cancer Research, 2025\u2022aacrjournals.org at https:\/\/aacrjournals.org\/clincancerres\/article\/31\/24\/5137\/770504","DOI":"10.1158\/1078-0432.CCR-25-0197"},{"key":"6982_CR123","doi-asserted-by":"crossref","unstructured":"Zhou X (2024) CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. nature.comX Zhou, Y Wang, Z Dou, G Delfanti, O Tsahouridis, CM Pellegry, M Zingarelli, G AtassiNature cancer, 2024\u2022nature.com 5, 1607\u20131621","DOI":"10.1038\/s43018-024-00830-0"},{"key":"6982_CR124","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11899-019-00521-z","volume":"14","author":"W Jiang","year":"2019","unstructured":"Jiang W et al (2019) Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus. Curr Hematol Malig Rep 14:247\u2013260","journal-title":"Curr Hematol Malig Rep"},{"key":"6982_CR125","doi-asserted-by":"crossref","unstructured":"Omer B et al (2018) Chimeric antigen receptor signaling domains differentially regulate proliferation and native T cell receptor function in virus-specific T cells. frontiersin.orgB Omer, PA Castillo, H Tashiro, T Shum, MTA Huynh, M Cardenas, M Tanaka, A LewisFrontiers in medicine, 2018\u2022frontiersin.org 5, 343","DOI":"10.3389\/fmed.2018.00343"},{"key":"6982_CR126","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.it.2025.04.007","volume":"46","author":"M Shahbazy","year":"2025","unstructured":"Shahbazy M et al (2025) Using TCR-CAR dual signaling for precise cancer targeting. Trends Immunol 46:435\u2013437","journal-title":"Trends Immunol"},{"key":"6982_CR127","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1158\/1078-0432.CCR-18-3199","volume":"25","author":"N Lapteva","year":"2019","unstructured":"Lapteva N et al (2019) T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor\u2013Expressing T Cells. Clin Cancer Res 25:7340\u20137350","journal-title":"Clin Cancer Res"},{"key":"6982_CR128","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jleuko\/qiad074","volume":"114","author":"T Bexte","year":"2023","unstructured":"Bexte T et al (2023) Nonviral technologies can pave the way for CAR-NK cell therapy. J Leukoc Biol 114:475\u2013486","journal-title":"J Leukoc Biol"},{"key":"6982_CR129","doi-asserted-by":"crossref","unstructured":"Harris E, Elmer JJ (2020) Optimization of electroporation and other non-viral gene delivery strategies for T cells. Biotechnol Prog 37","DOI":"10.1002\/btpr.3066"},{"key":"6982_CR130","doi-asserted-by":"publisher","unstructured":"Dowaidar M (2021) Nonviral gene delivery vectors for transfection of the CAR gene for CAR-T cell therapy. https:\/\/doi.org\/10.31219\/OSF.IO\/CKXH5","DOI":"10.31219\/OSF.IO\/CKXH5"},{"key":"6982_CR131","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/toxsci\/kfw220","volume":"155","author":"RM David","year":"2017","unstructured":"David RM, Doherty AT (2017) Viral Vectors: The road to reducing genotoxicity. Toxicol Sci 155:315\u2013325","journal-title":"Toxicol Sci"},{"key":"6982_CR132","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jcyt.2017.03.067","volume":"19","author":"T Kaartinen","year":"2017","unstructured":"Kaartinen T et al (2017) Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy 19:689\u2013702","journal-title":"Cytotherapy"},{"key":"6982_CR133","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D et al (2019) IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunol Res 7:759\u2013772","journal-title":"Cancer Immunol Res"},{"key":"6982_CR134","doi-asserted-by":"crossref","unstructured":"Arcangeli S et al (2020) Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. Front Immunol 11","DOI":"10.3389\/fimmu.2020.01217"},{"key":"6982_CR135","doi-asserted-by":"crossref","unstructured":"Zhang C (CK) and, Jones A (2020) Using serum-free media to streamline and optimize CAR T-cell manufacturing workflows. Cell Gene Ther. Insights 6, 1121\u20131126","DOI":"10.18609\/cgti.2020.121"},{"key":"6982_CR136","unstructured":"Kymriah | European Medicines Agency (EMA)[Online] Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kymriah. [Accessed: 24-Jan-2025]"},{"key":"6982_CR137","unstructured":"Yescarta | European Medicines Agency (EMA)[Online] Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta. [Accessed: 24-Jan-2025]"},{"key":"6982_CR138","unstructured":"Tecartus | European Medicines Agency (EMA)[Online] Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecartus. [Accessed: 24-Jan-2025]"},{"key":"6982_CR139","unstructured":"Breyanzi | European Medicines Agency (EMA)[Online] Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/breyanzi. [Accessed: 24-Jan-2025]"},{"key":"6982_CR140","unstructured":"Abecma | European Medicines Agency (EMA)[Online] Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abecma. [Accessed: 24-Jan-2025]"},{"key":"6982_CR141","unstructured":"Carvykti | European Medicines Agency (EMA)[Online] Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/carvykti. [Accessed: 24-Jan-2025]"},{"key":"6982_CR142","unstructured":"Logue J et al Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. ncbi.nlm.nih.govJM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, G Grillo, B CaoHaematologica, 2021\u2022ncbi.nlm. nih.gov at https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8017820\/"},{"key":"6982_CR143","doi-asserted-by":"crossref","unstructured":"Locke F (2045) (18)30864-7\/abstract> Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. thelancet.comFL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, Y LinThe lancet oncology, 2019\u2022thelancet.com at https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"6982_CR144","unstructured":"Ibrahim U et al Cytopenias Following CAR-T Cell Therapy-a Single Center Experience. tctjournal.org at https:\/\/www.tctjournal.org\/article\/S1083-8791(19)31351-5\/fulltext&gt"},{"key":"6982_CR145","doi-asserted-by":"crossref","unstructured":"Shouse G et al Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. ElsevierG Shouse, T Cao, J Zhang, M Mei, AF Herrera, L Nikolaenko, J Zain, T SiddiqiBlood, 2020\u2022Elsevier at https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497118721769","DOI":"10.1182\/blood-2020-143353"},{"key":"6982_CR146","doi-asserted-by":"crossref","unstructured":"Li H et al (2022) Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. Front Immunol 13","DOI":"10.3389\/fimmu.2022.1019548"},{"key":"6982_CR147","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC et al (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384:705\u2013716","journal-title":"N Engl J Med"},{"key":"6982_CR148","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726\u20131737","journal-title":"N Engl J Med"},{"key":"6982_CR149","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A et al (2020) Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transplant 26:26\u201333","journal-title":"Biol Blood Marrow Transplant"},{"key":"6982_CR150","unstructured":"Abramson J Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. thelancet.comJS Abramson, ML Palomba, LI Gordon, MA Lunning, M Wang, J Arnason, A Mehta, E PurevThe Lancet, 2020\u2022thelancet.com at https:\/\/www.thelancet.com\/article\/S0140-6736(20)31366-0\/abstract&gt"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06982-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:07:50Z","timestamp":1778756870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06982-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":150,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6982"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06982-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}